Research Projects & Grants

  • Randomized clinical trial assessing the effects of Pneumatic Vitreolysis on Vitreomacular traction (Protocol AG), Role: Investigator, (07/2019 - 07/2020) Status: Completed
  • Single-arm study assessing the effects of Pneumatic Vitreolysis on Macular Hole (Protocol AH), Role: Investigator, Status: Completed

Federal

  • Genetics in retinal diseases project, Role: PI, National Eye Institute/NIH/DHHS, (10/2024 - 10/2025) Status: Approved
  • Home OCT-Guided Treatment versus Treat and Extend for the Management of Neovascular AMD (Protocol AO), Role: PD/PI, Jaeb Center for Health Research, (11/2023 - 12/2024) Status: Awarded
  • Intravitreous Anti-VEGF treatment for prevention of vision threatening diabetic retinopathy in eyes at high risk, Role: PI, National Eye Institute/NIH/DHHS, (04/2022 - 04/2023) Status: Completed
  • Prompt panretinal photocoagulation versus intravitreal ranibizumab with deferred panretinal photocoagulation for proliferative diabetic retinopathy, Role: Investigator, National Eye Institute/NIH/DHHS, (01/2019 - 01/2020) Status: Completed
  • Randomized trial of Intravitreous Aflibercept versus Intravitreous Bevacizumab + deferred Aflibercept for treatment of central-involved diabetic macular edema (Protocol AC), Role: PI, National Institute on Minority Health and Health Disparities/NIH/DHHS, Status: Completed
  • Vitreous Proteomics in Eyes with a Macular Hole (Protocol AJ), Role: Investigator, Jaeb Center for Health Research, Status: Completed
  • A phase 2 Evaluation of Tonabersat for Diabetic Macular Edema (Protocol AN), Role: PI, Jaeb Center for Health Research, Status: Completed

For Profit Organization

  • A prospective, multicenter clinical study of the implantable miniature telescope, model SING in patients with central vision impairment associated with end-stage age-related macular degeneration (AMD), Role: Investigator, Samsara Vision, Inc, (08/2024 - 08/2025) Status: Approved
  • A Phase 2 Multicenter, Randomized, Double-Masked, Sham-Controlled Study of the Safety and Efficacy of Intravitreal Injections of NGM621 in Subjects with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD), Role: Investigator, NGM Biopharmaceuticals, Inc., (10/2022 - 10/2023) Status: Completed
  • A 64-week, two-arm, randomized, double-masked, multi-center, phase IIIb study assessing the efficacy and safety of Brolucizumab 6 mg compared to Aflibercept 2 mg in a treat-to-control regimen in patients with neovascular age-related macular degeneration (TALON), Role: Investigator, Novartis Pharmaceuticals Corporation, (08/2022 - 08/2023) Status: Completed
  • A Phase 2a, Prospective, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Assess the Safety, Tolerability and Evidence of Activity of a Single Intravitreal Injection of UBX1325 in Patients with Diabetic Macular Edema, Role: Investigator, Unity Biotechnology, Inc., (06/2022 - 06/2023) Status: Completed
  • VGFTe-ROP-1920, randomized controlled, multi-center study to assess the efficacy, safety, and tolerability of intravitreal aflibercept compared to laser photocoagulation in patients with retinopathy of prematurity, Role: Investigator, Regeneron Pharmaceuticals, Inc., (10/2021 - 10/2022) Status: Completed
  • An Extension Study to Evaluate the Long-Term Outcomes of Patients Who Received Treatment for Retinopathy of Prematurity in the VGFTe-ROP-1920 Study, Role: Investigator, Regeneron Pharmaceuticals, Inc., (01/2021) Status: Approved
  • A 12-Month, 2-Arm, randomized, double-masked, multicenter Phase III study assessing the efficacy and safety of Brolucizumab every 4 weeks versus Aflibercept every weeks in adult patients with visual impairment due to Diabetic Macular Edema (KINGFISHER), Role: Investigator, Novartis Pharmaceuticals Corporation, (09/2020 - 09/2021) Status: Completed
  • A Phase 2b multicenter dose-ranging study evaluating the safety and efficacy of a Long-acting Intravitreal Sunitinib Malate Depot Formulation (GB-102) compared to Intravitreal Aflibercept in subjects with Neovascular (Wet) Age-related Macular Degeneration (ALTISSIMO study), Role: PI, Graybug Vision, Inc., (09/2020 - 08/2021) Status: Completed
  • A phase 2/3, randomized, double-masked, sham-controlled trial of QPI-1007 delivered by single or multi-dose intravitreal injection(s) to subjects with acute nonarteritic anterior ischemic optic neuropathy (NAION), Role: Investigator, Quark Pharmaceuticals, (01/2019 - 01/2020) Status: Completed
  • Safety and efficacy of Abicipar Pegol (AGN-150998) in patients with neovascular age-related macular degeneration, Role: Investigator, Allergan Inc., (09/2018 - 09/2019) Status: Completed
  • A 24-week, double-masked, multicenter, two-arm extension study to collect safety and efficacy data on brolucizumab 6 mg drug product intended for commercialization in patients with neovascular age-related macular degeneration who have completed the CRTH258A2301 study, Role: Investigator, Novartis Pharmaceuticals Corporation, (07/2018 - 07/2019) Status: Completed
  • A two-year, randomized, double-masked, multi-center, three-arm study comparing the efficacy and safety of RTH258 versus aflibercept in subjects with neovascular age-related macular degeneration, Role: Investigator, Alcon Research Inc., (02/2018 - 02/2019) Status: Completed
  • RAINBOW study: A randomized, controlled study evaluating the efficacy and safety of Ranibizumab compared with laser therapy for the treatment of infants born prematurely with retinopathy of prematurity, Role: Investigator, Novartis Pharmaceuticals Corporation, (02/2018 - 02/2019) Status: Completed
  • A multicenter, open-label extension study to evaluate the long-term safety and tolerability of lampalizumab (FCFD4514S) in patients with geographic atrophy who have completed Genentech-sponsored lampalizumab studies, Role: Investigator, Genentech, Inc., (09/2017 - 09/2018) Status: Completed
  • Short-term evaluation of combination corticosteroid+anti-VEGF treatment for persistent central-involved diabetic macular edema following anti-VEGF therapy in pseudophakic eyes (protocol U), Role: Investigator, Diabetic Retinopathy Clinical Research Network (DRCRnet), (04/2017 - 04/2018) Status: Completed
  • A phase II, multicenter, randomized, single-masked, sham injection-controlled exposure-response study of lampalizumab intravitreal injections administered every two weeks or every four weeks to patients with geographic atrophy, Role: Investigator, Genentech, Inc., (10/2016 - 10/2017) Status: Completed

Internal

  • Effect of Hypochlorous Acid Disinfection on Ocular Flora Prior to Cataract Surgery, Role: Investigator, LLU Dept. of Ophthalmology, (09/2020) Status: Completed
  • Collection of vitreous and aqueous samples from patient undergoing vitrectomy and intravitreal injections, Role: Investigator, LLU Dept. of Ophthalmology, (03/2020) Status: Approved
  • Anterior chamber depth to axial length ratio as a predictor of post-surgical refractive outcome following uncomplicated cataract surgery, Role: Investigator, LLU Dept. of Ophthalmology, (05/2019) Status: Approved
  • Conjunctival floral resistance in a single practice site comparing povidone-iodine prep with or without post-injection second generation fluoroquinolones, Role: Investigator, LLU Dept. of Ophthalmology, (07/2018 - 07/2019) Status: Completed

Non-Profit Organization

  • Intravitreous anti-VEGF vs. prompt vitrectomy for vitreous hemorrhage from proliferative diabetic retinopathy (protocol AB), Role: Investigator, National Institute for Health Care Management Research and Educational Foundation, (03/2020 - 03/2021) Status: Completed